Nolvadex (Tamoxifen Citrate)

Nolvadex (tamoxifen citrate) acts on estrogen‑dependent breast tissue and is indicated for several breast‑cancer related conditions.

• Estrogen receptor‑positive breast cancer: slows tumor growth and improves survival.
• Adjuvant therapy for early‑stage breast cancer: reduces risk of disease recurrence after surgery.
• Metastatic breast cancer: prolongs progression‑free and overall survival in advanced disease.
• Prevention of breast cancer in high‑risk women: lowers incidence of new breast tumors.

• Tamoxifen citrate binds competitively to estrogen receptors in breast tissue, acting as an antagonist that blocks estrogen‑driven transcription. In other tissues it exhibits partial agonist activity, modulating gene expression without stimulating proliferation. This selective receptor modulation inhibits estrogen‑stimulated growth of breast cancer cells while preserving some estrogenic effects elsewhere, accounting for its therapeutic profile. The drug’s high affinity for ERα and ERβ results in sustained receptor occupancy, contributing to its long half‑life and clinical efficacy.

Tamoxifen citrate may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Hot flashes: transient feeling of warmth and sweating.
• Nausea or vomiting: mild gastrointestinal upset.
• Fatigue: general tiredness or reduced energy.
• Menstrual irregularities: changes in cycle length or flow.

Serious or Rare Side Effects

• Deep vein thrombosis or pulmonary embolism: blood clots in veins or lungs.
• Endometrial cancer: abnormal growth of uterine lining.
• Severe liver injury: jaundice, elevated enzymes, or hepatic failure.

When prescribing tamoxifen citrate, clinicians should observe several precautionary measures to ensure patient safety.

• Assess thromboembolic risk: evaluate history of clotting disorders before initiation.
• Monitor liver function: perform baseline and periodic hepatic enzyme tests.
• Evaluate endometrial health: conduct gynecologic assessment for abnormal uterine bleeding.
• Counsel on pregnancy avoidance: drug is contraindicated in pregnancy due to fetal risk.
• Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture and light.

Tamoxifen citrate interacts with several medicines; awareness of the interaction level guides clinical management.

Major Interactions (Avoid)

• Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): markedly reduce tamoxifen activation.
• Anticoagulants (e.g., warfarin): increase risk of bleeding when combined.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower tamoxifen plasma concentrations.
• Hormonal contraceptives: potential reduced efficacy of contraceptive effect.
• SSRIs with moderate CYP2D6 inhibition (e.g., sertraline): may modestly affect tamoxifen metabolism.